On Monday the FDA required new safety warnings on all GLP-1 medications after evidence of a potential higher risk of nonarteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden, permanent vision loss; a causal link is not established. An analysis of 126 trials with more t